Loading...

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone

BACKGROUND: The optimal sequence of the multiple active agents now available for metastatic castration-resistant prostate cancer (mCRPC) is unclear. Prior reports have suggested diminished responses to sequential lines of androgen receptor (AR)-targeted therapies, but it is unknown whether subsequen...

Full description

Saved in:
Bibliographic Details
Main Authors: Suzman, Daniel L., Luber, Brandon, Schweizer, Michael T., Nadal, Rosa, Antonarakis, Emmanuel S.
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4144818/
https://ncbi.nlm.nih.gov/pubmed/25053178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22844
Tags: Add Tag
No Tags, Be the first to tag this record!